Clinical Trial Participation

Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances | 10/13/2020

… National Institutes of Health Revitalization Act of 1993 publicized the critical need to expand access to clinical trials to include women and racial and/or ethnic minorities. 3 Racial and ethnic inequities in cancer clinical trial participation are well established, with access barriers including competing demands (time and financial burden) and mistrust (fears of mistreatment, unknown research procedures, and unintended consequences). 4 - 6 Telehealth can ameliorate these long‐standing access …

Impact of SARS-CoV-2 & COVID-19 on Volunteer Interest in Clinical Trial Participation, Upcoming Webinar Hosted by Xtalks | PRWeb | 9/15/2020

Impact of SARS-CoV-2 & COVID-19 on Volunteer Interest in Clinical Trial Participation, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss a strong COVID-19 risk mitigation plan, which is critical to maintaining safety, interest and participation and why limiting the entry of the virus into the research unit should include strict monitoring. Attendees will learn how the spread of the …

Black Health Matters Launches Breast Cancer Initiative In research Clinical Study | 9/10/2020

From: prnewswire.com Raising Awareness of Clinical Trial Participation Using Social Media Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation . This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of color with breast cancer. The campaign …

Press Release: Illingworth Research Joins Avoca Quality Consortium | 9/10/2020

… Quality Consortium. This membership gives access to a wider network of over 120 pharma, biotech, and clinical service provider companies who all share a similar vision; to enhance and improve the patient experience of clinical trial participation . The consortium, founded in 2011, provides an exciting new space to share ideas, access training sessions and discuss industry developments. Illingworth is the first member of the consortium that can offer a truly …

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | Business Wire | 9/3/2020

… Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and …

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | Business Wire | 9/3/2020

… Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and …

** | 9/3/2020**

… Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and …

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 - Scientific Technology News | 9/3/2020

… Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and …

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 Swiss Stock Exchange:RO | Globe Newswire | 9/3/2020

… Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and …

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | 9/3/2020

… Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and …

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 | 9/3/2020

… Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and …

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | BioSpace | 9/3/2020

… Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and …

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 | 9/3/2020

… Annual Meeting 2019, which showed higher OCREVUS exposure was associated with lower B-cell levels and with greater control of disability progression, without impacting safety. Roche is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterisation of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-centre Phase IV study evaluating disease activity and …

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | 9/3/2020

… Meeting 2019, which showed higher Ocrevus exposure was associated with lower B-cell levels and with less disability progression, without any associated impact on safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an open-label, multi-center Phase IV study evaluating disease activity and …

Black Health Matters Launches Breast Cancer Initiative In research Clinical Study | 9/1/2020

Black Health Matters Launches Breast Cancer Initiative In research Clinical Study PRN 1 day ago NEW YORK: Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation . This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of …

Cancer Research: The Lessons to Learn from COVID-19 [Science in Society] | 9/1/2020

… a barrier to participation for patients who live far away. The time commitment required to make frequent visits to the center can therefore be significant, and this contributes to the financial disincentives that hinder clinical trial participation . The need to travel might exacerbate the profound difficulty in compiling representative samples that include a broad range of ethnic minority groups, as well as patients from more disadvantaged socioeconomic backgrounds or rural …

Discussion on cancer screening, continuation of treatment crucial during COVID-19 pandemic | 8/31/2020

… the country where the coronavirus infection rate is pretty high, you should work with your doctor to do everything possible to get treatment.” National trends have shown a dramatic decrease in cancer screenings and clinical trial participation since the start of the pandemic. The reduction in routine screenings could lead to 10,000 or more excess deaths from breast and colorectal cancers within the next decade, NCI Director Norman E. “Ned …

Black Health Matters Launches Breast Cancer Initiative In research Clinical Study | PR Newswire | 8/20/2020

NEW YORK Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation . This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of color with breast cancer. The campaign will capture the voice of the female and male …

Black Health Matters Launches Breast Cancer Initiative In research Clinical Study | 8/20/2020

… Save NEW YORK , Aug. 20, 2020 /PRNewswire/ – Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation . This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of color with breast cancer. The campaign will capture the voice …

Black Health Matters Launches Breast Cancer Initiative In research Clinical Study | BioSpace | 8/20/2020

NEW YORK Black Health Matters, the leading health and chronic disease management platform for African Americans will launch a social media campaign to raise awareness of breast cancer and clinical trial participation . This focus will introduce new content to be socialized on Facebook, Twitter and Instagram in a campaign that will speak to people of color with breast cancer. The campaign will capture the voice of the female and male …

TargetCancer Foundation Announces Rare Cancer Precision Medicine Research Initiative | 8/16/2020

… communities. TRACK aims to provide the treatment care team with individualized treatment recommendations, informed by genomic analysis and in consultation with field-leading rare cancer clinicians and researchers. TRACK challenges the traditional paradigm of clinical trial participation by incorporating remote consent, enabling patients to access genomic information and tailored treatment recommendations without the typical requirement to travel to an academic medical center. TargetCancer Foundation, a patient-founded not-for-profit …

Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results | PR Newswire | 8/11/2020

… PSC) have resumed enrollment. Through close coordination with over 100 global trial sites, Pliant has continued to conduct site initiation activities throughout the COVID-19 pandemic. The Company is offering a hybrid approach to clinical trial participation with home-health solutions designed to minimize the requirements for visits to healthcare facilities, as well as a campaign to raise awareness of the IPF and PSC programs across patient communities and patient …

Medidata Congratulates ‘Tu Salud Tu Familia’ for Its Capital Emmy® Award | Business Wire | 8/10/2020

… today’s most pressing healthcare issues,” said Dr. Sandoval. “We are grateful to have Medidata’s support and partnership to amplify our message and to help improve our engagement with the community, including sharing information on clinical trial participation . We celebrate this wonderful Emmy Award recognition with them!” About Medidata Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights …

BBK Worldwide Creative Director, Patient Experience and Engagement, Jessica Kim Named to PharmaVOICE 100 | PR Newswire | 8/7/2020

… as well as text messaging, gamification, medication reminders, and content-rich podcasts. Recently, Ms. Kim helped spearhead Study-Life Balance – a new construct that leverages patient-centric solutions to help patients more easily integrate clinical trial participation into their daily lives. Study-Life Balance was inspired by today’s empowered healthcare consumer who has expectations for an enhanced healthcare journey. By putting clinical trial participation within the context of the patient’s …

Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes | 8/7/2020

Enter your email address below. Email or Customer ID Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account. Request Username Can’t sign in? Forgot your username? Enter your email address below and we will send you your username Email or …

Medicaid

Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances | 10/13/2020

… Aeronautics and Space Administration (NASA) establishing the modality to treat astronauts. 1 Twenty years ago, the Centers for Medicare and Medicaid Services began reimbursing remote services in rural and underserved areas. 2 To our knowledge … or ethnic minorities. 3 Racial and ethnic inequities in cancer clinical trial participation are well established, with access barriers including competing demands (time and financial burden) and mistrust (fears of mistreatment, unknown research procedures, and …

Calculating the Costs of Clinical Trials | 12/1/2019

… the trial ends. ASH Clinical News recently spoke with several clinical trial and ethics experts about the hidden costs of clinical trial participation, the prices of post-trial access to investigational drugs, and some of … requirements that clinical trials must meet to qualify.) Coverage through Medicaid varies on a state-by-state basis, however, and defining “routine care” can be a bit of a gray area. “If you are enrolled …

Medicare

Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances | 10/13/2020

… the National Aeronautics and Space Administration (NASA) establishing the modality to treat astronauts. 1 Twenty years ago, the Centers for Medicare and Medicaid Services began reimbursing remote services in rural and underserved areas. 2 To … or ethnic minorities. 3 Racial and ethnic inequities in cancer clinical trial participation are well established, with access barriers including competing demands (time and financial burden) and mistrust (fears of mistreatment, unknown research procedures, and …

Calculating the Costs of Clinical Trials | 12/1/2019

… the trial ends. ASH Clinical News recently spoke with several clinical trial and ethics experts about the hidden costs of clinical trial participation, the prices of post-trial access to investigational drugs, and some of … with participation in the trial.” 4 Private insurance companies and Medicare must cover routine patient costs for qualifying clinical trials. (See SIDEBAR on page 48 for the long list of requirements that clinical trials must …

Clinical Research

Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances | 10/13/2020

… cancer prevention, early detection, and treatment research going forward. History of Telehealth and Barriers to the Use of Telehealth in Clinical Research History has taught us to adapt and learn from crises to improve how … or ethnic minorities. 3 Racial and ethnic inequities in cancer clinical trial participation are well established, with access barriers including competing demands (time and financial burden) and mistrust (fears of mistreatment, unknown research procedures, and …

Medidata Congratulates ‘Tu Salud Tu Familia’ for Its Capital Emmy® Award | Business Wire | 8/10/2020

… importance of different health issues. It was created and is hosted by Dr. Fabian Sandoval, CEO and Medical Director, Emerson Clinical Research Institute. Medidata, along with Genentech, has been sponsoring the program since its inception … improve our engagement with the community, including sharing information on clinical trial participation. We celebrate this wonderful Emmy Award recognition with them!” About Medidata Medidata is leading the digital transformation of life sciences, creating hope …

National Institutes of Health

Impact of the COVID‐19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances | 10/13/2020

National Institutes of Health Revitalization Act of 1993 publicized the critical need to expand access to clinical trials to include women and racial and/or ethnic minorities. 3 Racial and ethnic inequities in cancer clinical trial participation are well established, with access barriers including competing demands (time and financial burden) and mistrust (fears of mistreatment, unknown research procedures, and unintended consequences). 4 - 6 Telehealth can ameliorate these long‐standing access …

Nature paper outlines possibilities of digital clinical trails | MobiHealthNews | 8/28/2020

… Nature discusses the potentials and challenges of digital clinical trials. The paper builds on a workshop held by the U.S. National Institutes of Health and the National Science Foundation in April of 2019. One of … long clinical trial timelines, all of which contribute to low clinical trial participation: for example, only about 8% of cancer patients enroll in cancer trials,” authors of the paper wrote. “Enter the concept of digital …

Food and Drug Administration

Impact of SARS-CoV-2 & COVID-19 on Volunteer Interest in Clinical Trial Participation, Upcoming Webinar Hosted by Xtalks | PRWeb | 9/15/2020

Impact of SARS-CoV-2 & COVID-19 on Volunteer Interest in Clinical Trial Participation, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss a strong COVID-19 risk … response to the pandemic’s impact on clinical trial continuity, the Food and Drug Administration (FDA) acted swiftly with the publication of new guidelines and strategies on how sponsors and investigative sites could adapt to the …

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers | BMJ | 3/16/2020

… could provide a treatment option for medication that would otherwise be unavailable—whether due to not being approved by the Food and Drug Administration (FDA), not approved for the indication of SLE or not affordable … experienced) Patients were equally proactive in discussing the disadvantages of clinical trial participation. Participants were particularly concerned about the unknown aspects of clinical trial participation, especially the outcome and side effects experienced. For newer therapies …

NIH

Calculating the Costs of Clinical Trials | 12/1/2019

… trial participation Of the three potential risks of participating in a clinical trial listed on the National Institutes of Health (NIH) website, two are related to the potential costs, hidden and otherwise: People who participate … clinical trial and ethics experts about the hidden costs of clinical trial participation, the prices of post-trial access to investigational drugs, and some of the steps being taken to ease this burden. What’s Covered …

Calculating the Costs of Clinical Trials | 12/1/2019

… trial participation Of the three potential risks of participating in a clinical trial listed on the National Institutes of Health (NIH) website, two are related to the potential costs, hidden and otherwise: People who participate … clinical trial and ethics experts about the hidden costs of clinical trial participation, the prices of post-trial access to investigational drugs, and some of the steps being taken to ease this burden. What’s Covered …

American College of Rheumatology

Genentechs Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared To Standard of Care Alone | 11/10/2019

… infections (6% vs.18% in placebo group) were not increased with Gazyva. These data will be presented at the 2019 American College of Rheumatology (ACR) Annual Meeting in Atlanta, Georgia, on November 10, 2019 (Abstract … to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech is taking action to recruit a broader, more diverse population …

Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone – Company Announcement - FT.com | Financial Times | 11/9/2019

… infections (6% vs.18% in placebo group) were not increased with Gazyva. These data will be presented at the 2019 American College of Rheumatology (ACR) Annual Meeting in Atlanta, Georgia , on November 10, 2019 (Abstract … to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech is taking action to recruit a broader, more diverse population …

National Cancer Institute

Sex disparities ‘pervasive’ in cancer clinical trial participation | 10/15/2019

Sex-based disparities remain pervasive in cancer clinical trial participation, according to results of a retrospective meta-analysis published in Journal of the National Cancer Institute. Researchers observed underrepresentation of women primarily in noncooperative-group-supported trials, which account for the majority of randomized controlled trials. “In totality, we tried to mirror how other studies have been modeled to give an update on what disparities in clinical trials look like …

New Patient Resource from NCCN Helps People with Bladder Cancer Make Informed Treatment Decisions | PR Newswire | 6/26/2019

… to take notes. “There have been five new drug approvals for bladder cancer in the last few years, and increasing clinical trial participation has been key to these advances. We’ve definitely turned a corner, and … Members of the National Clinical Trial Network, including SWOG, its National Cancer Institute partners, and our industry collaborators continue to work tirelessly to raise the bar with clinical trials that can lead to changes in …

Clinical Trial Recruitment

Cancer patients often need this one basic thing to participate in clinical trials | 10/11/2019

… clinical trial participation: finding a suitable study and paying out-of-pocket costs, such as transportation and lodging. But Dornsife now has a more ambitious crusade, one that aims to do nothing less than change the status quo. “The goal,” says the Lazarex website, “is to permanently fix the clinical trial recruitment system by shifting the financial burden of participation from the patient to the pharmaceutical companies who need patients …

Cancer patients often need this one basic thing to participate in clinical trials | 10/11/2019

… clinical trial participation: finding a suitable study and paying out-of-pocket costs, such as transportation and lodging. But Dornsife now has a more ambitious crusade, one that aims to do nothing less than change the status quo. “The goal,” says the Lazarex website, “is to permanently fix the clinical trial recruitment system by shifting the financial burden of participation from the patient to the pharmaceutical companies who need patients …

Centers for Medicare and Medicaid Services

UsAgainstAlzheimer’s Applauds the Bipartisan Introduction of the CHANGE Act, Critical Legislation to Promote Early Diagnosis of Alzheimer’s | PR Newswire | 4/10/2019

Centers for Medicare and Medicaid Services (CMS) to require the use of cognitive impairment detection tools identified by the National Institutes of Health. The bill would also direct CMS to incentivize the detection and diagnosis of Alzheimer’s disease or related dementias and promote care planning services, including potential for clinical trial participation, which have historically had low levels of engagement, particularly among communities of color. “I thank this bipartisan group …

FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | CNBC | 12/1/2017

… estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy– –The Centers for Medicare and Medicaid Services issued a preliminary National Coverage Determination (NCD) for FoundationOne … immunotherapies; a tool for physicians that identifies patient opportunities for clinical trial participation; and, an FDA-approved platform for companion diagnostic development for biopharma companies developing precision therapeutics. FoundationOne CDx assesses all classes of genomic …

Genentech

Medidata Congratulates ‘Tu Salud Tu Familia’ for Its Capital Emmy® Award | Business Wire | 8/10/2020

… was created and is hosted by Dr. Fabian Sandoval, CEO and Medical Director, Emerson Clinical Research Institute. Medidata, along with Genentech, has been sponsoring the program since its inception in 2019, recognizing the importance of … improve our engagement with the community, including sharing information on clinical trial participation. We celebrate this wonderful Emmy Award recognition with them!” About Medidata Medidata is leading the digital transformation of life sciences, creating hope …

Medidata Congratulates ‘Tu Salud Tu Familia’ for Its Capital Emmy® Award | Business Wire | 8/10/2020

… was created and is hosted by Dr. Fabian Sandoval, CEO and Medical Director, Emerson Clinical Research Institute. Medidata, along with Genentech, has been sponsoring the program since its inception in 2019, recognizing the importance of … improve our engagement with the community, including sharing information on clinical trial participation. We celebrate this wonderful Emmy Award recognition with them!” About Medidata Medidata is leading the digital transformation of life sciences, creating hope …

Biogen

Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone - Valdosta Daily Times | Business Wire | 11/9/2019

… are two to three times more likely than Caucasian women to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech … system. Gazyva is part of a collaboration between Genentech and Biogen. Combination studies investigating Gazyva with other approved or investigational medicines, including cancer immunotherapies and small molecule inhibitors, are underway across a range of blood …

Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared to Standard of Care Alone | Business Wire | 11/9/2019

… are two to three times more likely than Caucasian women to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech … system. Gazyva is part of a collaboration between Genentech and Biogen. Combination studies investigating Gazyva with other approved or investigational medicines, including cancer immunotherapies and small molecule inhibitors, are underway across a range of blood …

Pfizer

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting | PR Newswire | 11/7/2019

… 8-13, 2019 . In addition, results of two positive clinical studies conducted by LRA’s affiliate Lupus Therapeutics (LT) in collaboration with Pfizer and the Rilite Foundation focus on improving how lupus disease activity is monitored. The … with lupus and family members can work collaboratively to accelerate clinical trial participation in lupus and drug discovery. About Lupus Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than …

Cancer patients often need this one basic thing to participate in clinical trials | 10/11/2019

… later, the Flourtown retiree, 67, is going strong, thanks to participating in clinical testing of a targeted drug developed by Pfizer. Lorbrena was approved last November, and it is still keeping Bagga’s cancer at bay … than 4,000 cancer patients overcome the well-documented barriers to clinical trial participation: finding a suitable study and paying out-of-pocket costs, such as transportation and lodging. But Dornsife now has a more ambitious …

MD Anderson Cancer Center

Precision Medicine Research Project Focuses on Rare Cancers | HealthIT Analytics | 8/6/2020

… and precision medicine to provide patients and providers with personalized treatment recommendations. TRACK aims to challenge the traditional method of clinical trial participation by incorporating remote consent, allowing patients to access genomic information and tailored … The University of California San Diego and University of Texas MD Anderson Cancer Center will serve as enrolling sites for the study. Participants will also have the option to enroll remotely in the study with …

Sex disparities ‘pervasive’ in cancer clinical trial participation | 10/15/2019

Sex-based disparities remain pervasive in cancer clinical trial participation, according to results of a retrospective meta-analysis published in Journal of the National Cancer Institute. Researchers observed underrepresentation of women primarily in noncooperative-group … Ludmir, MD, resident radiation oncologist at The University of Texas MD Anderson Cancer Center, told HemOnc Today . “It’s hard to exactly assess the impact of these disparities on clinical research. When we run these clinical …

Mayo Clinic

New Patient Resource from NCCN Helps People with Bladder Cancer Make Informed Treatment Decisions | PR Newswire | 6/26/2019

… to take notes. “There have been five new drug approvals for bladder cancer in the last few years, and increasing clinical trial participation has been key to these advances. We’ve definitely turned a corner, and … H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL …

CISCRP’s Free Community Health Event Coming to Jacksonville, FL | PRWeb | 11/22/2017

… will interact with local researchers, clinical trial participants, health care professionals, and advocacy groups, to learn about clinical research and clinical trial participation. Attendees will also have access to health screenings, including blood pressure, BMI … hope to patients,” says Charles Burger, M.D., professor of medicine, Mayo Clinic College of Medicine and Science, and keynote speaker. “At Mayo Clinic, the true purpose of research is to address the unmet needs of …

Levi Garraway

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | Business Wire | 9/3/2020

… committed to following the science to reduce relapses in NMOSD and slow and eventually stop disease progression in MS,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “From the … safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an …

Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020 | Business Wire | 9/3/2020

… committed to following the science to reduce relapses in NMOSD and slow and eventually stop disease progression in MS,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “From the … safety. Genentech is also deeply committed to addressing barriers to clinical trial participation and advancing inclusive research. The study design of the recently initiated CHIMES (CHaracterization of ocrelizumab In Minorities with multiplE Sclerosis) trial, an …

Sandra Horning

FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis – Company Announcement - FT.com | Financial Times | 9/18/2019

… options are needed for lupus nephritis, a potentially life-threatening inflammation of the kidneys that most commonly affects women,” said Sandra Horning , M.D., chief medical officer and head of Global Product Development. “We are committed … to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech is taking action to recruit a broader, more diverse population …

FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis | Business & Finance | heraldchronicle.com | Business Wire | 9/18/2019

… options are needed for lupus nephritis, a potentially life-threatening inflammation of the kidneys that most commonly affects women,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We are committed … to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech is taking action to recruit a broader, more diverse population …